UPS: ‘The market for drugs and therapies requiring cold storage is growing at a rapid rate’ UPS Healthcare says it has invested in its suite of cold chain technologies on the back of ‘unreal growth’ in the pharmaceutical cold chain market.
The company cited data from Biopharma Cold Chain Sourcebook, which predicts that cold chain trends will grow 48% between 2018 and 2024 for drugs that require at least 2-8°C storage and shipping. Additionally, cold chain services market growth is expected to accelerate over the next three years, said UPS, increasing by 24% by 2024, after posting a 10% increase from 2019 to 2020.
On top of that, the US Food and Drug Administration (FDA) is continually approving more and more cold storage drugs, noted the logistics expert.
The World Health Organization (WHO) and the Swiss Confederation have launched the first WHO BioHub Facility to enhance the rapid sharing of viruses and other pathogens between laboratories and partners globally.
Trelleborg helps wearables firms navigate new EU regulation The medical device tech firm is poised to assist manufacturers in navigating the new European Medical Device Regulation, which goes into effect this week.
Navigating the global regulatory landscape can be confusing for anyone in the life-sciences realm, including manufacturers that make wearable sensors and other medical devices. To that end, Trelleborg Healthcare and Medical is offering manufacturers that supply such products to European clients resources (including a free webinar) geared toward helping them understand and comply with the Medical Device Regulation (MDR), which goes into effect May 26.
The new MDR is intended to help protect patients from risks that may be posed by a range of medical products. Florance Veronelli, segment manager with Trelleborg Sealing Solutions, talked about the assistance offered by the firm, and what the regulation means for the industry.
UK regulator reviews AstraZeneca’s Alexion acquisition The UK’s Competition and Markets Authority (CMA) is inviting comments on AstraZeneca’s $39bn acquisition of Alexion.
Announced in December, the acquisition of Boston-based Biotech Alexion Pharmaceuticals, Inc., will support AstraZeneca’s ambitions to develop novel medicines in immunology. It is set to be AstraZeneca’s
Today the CMA announced the launch of a merger inquiry, which is
open for comments until June 3, 2021. The CMA will decide on July 21 whether to refer the merger for a Phase 2 investigation. The CMA is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the UK for
FDA leader discusses breaking barriers in clinical care Acting FDA commissioner Janet Woodcock explains how government, researchers, doctors and patients can contribute to improving the clinical research system.
With more than three decades of experience at the US Food and Drug Administration (FDA), acting commissioner Janet Woodcock has an informed perspective of the government’s contributions to pharmaceutical development, drug safety, and clinical research. She’s seen the agency work closely with the National Institutes of Health, she said, and witnessed “tremendous progress” on encouraging a stronger focus on the clinical trials included in government grants.
“
The experience we’ve had working and trying to deal with the coronavirus has shown the power of everybody working together,” she told Outsourcing-Pharma. “